Loading...
LNAI logo

Lunai Bioworks Inc.NasdaqCM:LNAI Stock Report

Market Cap US$12.4m
Share Price
n/a
1Y-88.5%
7D-14.7%
1D-0.4%
Portfolio Value
​
View

Lunai Bioworks Inc.

NasdaqCM:LNAI Stock Report

Market Cap: US$12.4m

Lunai Bioworks (LNAI) Stock Overview

A pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. More details

LNAI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Negative shareholders equity

Earnings have declined by 24.4% per year over past 5 years

Highly volatile share price over the past 3 months compared to the US market

+ 2 more risks

LNAI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW487,274 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
487,274 investors already sharing narratives
View all narratives

Lunai Bioworks Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lunai Bioworks
Historical stock prices
Current Share PriceUS$2.73
52 Week HighUS$28.80
52 Week LowUS$1.21
Beta0.35
1 Month Change19.21%
3 Month Change-7.99%
1 Year Change-88.52%
3 Year Change-93.56%
5 Year Change-99.25%
Change since IPO-99.50%

Recent News & Updates

Recent updates

Seeking Alpha • Oct 17

Enochian stock climbs on US patent for oncology platform

Enochian BioSciences (NASDAQ:ENOB) stock rose ~5% on Monday after the company said that it received a U.S. patent for its proprietary cancer treatment platform which could potentially be used to induce life-long remission. Preclinical animal and laboratory studies of the company’s product candidate to treat pancreatic cancer in humanized mice model of hu-BLT (ENOB-DC-11) have shown positive results, the company added. "We are incredibly excited to have been awarded this patent for Enochian’s allogeneic cell and gene therapy cancer treatment platform, especially following promising early study results," said Enochian's CEO Mark Dybul. Enochian noted that if results remain positive, it will potentially submit a pre-IND application to the FDA by early- to mid-2023, followed by IND submission and human trials planned for the end of 2023 or early 2024. The company hopes to expand its oncology treatment platform to product candidates which could include triple-negative breast cancer, glioblastoma and/or kidney cancer.
Seeking Alpha • Jul 01

Enochian BioSciences discovers two sets of altered animal data in two of its studies

After an internal review of its scientific data, Enochian BioSciences (NASDAQ:ENOB) has discovered that a former scientific advisor had altered and falsified two sets of animal data before the company's scientists could review it. "One data set was for an inhaled COVID-19 treatment study while the other was for a (hepatitis B virus) therapy study," the biotech company said in a statement on Friday. As a result of its discovery, the company said it would initiate legal action against the former scientific advisor, Serhat Gumrukçu. ENOB said that its investigation verified certain data from the COVID-19 and (hepatitis B virus) pipelines. "The company is evaluating its internal controls regarding the review and verification of external scientific data and will modify as appropriate," ENOB said. ENOB stock -4.7% to $1.84 in aftermarket trading.
Analysis Article • Jun 28

Is Enochian Biosciences (NASDAQ:ENOB) Using Debt Sensibly?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analysis Article • Feb 20

Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Oct 30

Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Jun 26

Enochian Biosciences: A Follow Through For An HIV Cure

ENOB announced on June 14, 2021, that it has entered into a 29 million registered direct offering, improving its sustainability. Its Pre-IND request for a potential HIV cure has been approved by the FDA. On June 21, 2021, the company announced that they acquired an exclusive license for an Inhaled Treatment and Prevention Technology to potentially treat and prevent all variants of the Coronavirus. ENOB is expected to burn more cash in the coming years, but on the brighter side, institutions backed them up as they are starting to generate good results for their investors.
Analysis Article • Feb 14

Do Insiders Own Lots Of Shares In Enochian Biosciences, Inc. (NASDAQ:ENOB)?

If you want to know who really controls Enochian Biosciences, Inc. ( NASDAQ:ENOB ), then you'll have to look at the...

Shareholder Returns

LNAIUS BiotechsUS Market
7D-14.7%3.4%-0.4%
1Y-88.5%37.9%18.4%

Return vs Industry: LNAI underperformed the US Biotechs industry which returned 37.9% over the past year.

Return vs Market: LNAI underperformed the US Market which returned 18.4% over the past year.

Price Volatility

Is LNAI's price volatile compared to industry and market?
LNAI volatility
LNAI Average Weekly Movement21.9%
Biotechs Industry Average Movement10.5%
Market Average Movement7.3%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: LNAI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: LNAI's weekly volatility has decreased from 32% to 22% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a29David Weinsteinwww.lunaibioworks.com

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer.

Lunai Bioworks Inc. Fundamentals Summary

How do Lunai Bioworks's earnings and revenue compare to its market cap?
LNAI fundamental statistics
Market capUS$12.42m
Earnings (TTM)-US$128.28m
Revenue (TTM)US$20.94k
591.0x
P/S Ratio
-0.1x
P/E Ratio

Is LNAI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LNAI income statement (TTM)
RevenueUS$20.94k
Cost of RevenueUS$0
Gross ProfitUS$20.94k
Other ExpensesUS$128.30m
Earnings-US$128.28m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-28.29
Gross Margin100.00%
Net Profit Margin-612,568.11%
Debt/Equity Ratio-10.4%

How did LNAI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/09 21:43
End of Day Share Price 2026/07/09 00:00
Earnings2026/03/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lunai Bioworks Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.